SCHEMBL6203062

SCHEMBL6203062

COc1cc2c(cc1OC)-c1[nH]c3ccc(OCCN(C)C)cc3c1C2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.46
ESR1 P03372 3/20 0.46
KDR P35968 2/20 0.46
TOP2A P11388 2/20 0.45
TOP1 P11387 1/20 0.43
FLT3 P36888 1/20 0.42
HTR1A P08908 2/20 0.41
HTR1D P28221 2/20 0.41
HTR7 P34969 2/20 0.41
HTR5A P47898 2/20 0.41
HTR6 P50406 2/20 0.41
SLC6A4 P31645 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
TNKS O95271 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7235812 0.99 PARP1 (0.45) PARP1ESR1KDRTOP2ATOP1
SCHEMBL6202601 0.90 KDM4E (0.47) PARP1ESR1KDRTOP2AFLT3
Hydrochloric Acid SCHEMBL7236341 0.89 KDM4E (0.46) PARP1ESR1KDRTOP2AFLT3
SCHEMBL7236414 0.88 PARP1 (0.38) PARP1ESR1KDRTOP2ATOP1
SCHEMBL6203316 0.86 PARP1 (0.47) PARP1ESR1KDRTOP2ATOP1
SCHEMBL6197999 0.85 TOP2A (0.54) PARP1ESR1TOP2ATOP1HTR1A
Hydrochloric Acid SCHEMBL7227737 0.85 PARP1 (0.46) PARP1ESR1KDRTOP2ATOP1
Hydrochloric Acid SCHEMBL7236484 0.84 TOP2A (0.53) PARP1ESR1TOP2ATOP1HTR1A
SCHEMBL7236389 0.84 TOP1 (0.43) PARP1TOP1FLT3HTR1AHTR1D
SCHEMBL6202476 0.84 PARP1 (0.46) PARP1ESR1KDRTOP2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1266887-B1 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-08-17 EP disclosed
US-6627650-B2 An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. LES LABORATOIRES SERVIER (FR) 2003-09-30 US disclosed
US-20030125369-A1 Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent LES LABORATOIRES SERVIER (FR) 2003-07-03 US disclosed
EP-1266887-A2 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125369-A1 Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent IDO1, IDO2, AHR PARP1 265/4885ESR1 1495/4885KDR 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.